VIRX vs. SPRB, DARE, ACXP, IPA, FBIO, THTX, NRXP, BCTX, ENLV, and MRKR
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Spruce Biosciences (SPRB), Daré Bioscience (DARE), Acurx Pharmaceuticals (ACXP), ImmunoPrecise Antibodies (IPA), Fortress Biotech (FBIO), Theratechnologies (THTX), NRx Pharmaceuticals (NRXP), BriaCell Therapeutics (BCTX), Enlivex Therapeutics (ENLV), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical preparations" industry.
Viracta Therapeutics (NASDAQ:VIRX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking.
Viracta Therapeutics has a net margin of 0.00% compared to Spruce Biosciences' net margin of -474.96%. Spruce Biosciences' return on equity of -52.31% beat Viracta Therapeutics' return on equity.
Viracta Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 821.05%. Spruce Biosciences has a consensus price target of $5.67, indicating a potential upside of 580.52%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viracta Therapeutics is more favorable than Spruce Biosciences.
31.4% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 7.4% of Viracta Therapeutics shares are held by company insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Viracta Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500.
Spruce Biosciences has higher revenue and earnings than Viracta Therapeutics. Spruce Biosciences is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Spruce Biosciences received 12 more outperform votes than Viracta Therapeutics when rated by MarketBeat users. However, 72.22% of users gave Viracta Therapeutics an outperform vote while only 64.41% of users gave Spruce Biosciences an outperform vote.
In the previous week, Viracta Therapeutics had 5 more articles in the media than Spruce Biosciences. MarketBeat recorded 7 mentions for Viracta Therapeutics and 2 mentions for Spruce Biosciences. Viracta Therapeutics' average media sentiment score of 0.89 beat Spruce Biosciences' score of 0.43 indicating that Viracta Therapeutics is being referred to more favorably in the media.
Summary
Viracta Therapeutics beats Spruce Biosciences on 9 of the 17 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viracta Therapeutics Competitors List
Related Companies and Tools
